PCI Biotech: Annual Report 2014

The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report
2014. The Board of Directors has decided to present the Annual Report 2014 to
the ordinary general assembly scheduled to 12 May 2015. The Annual Report 2014
is attached.

About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in
Norway and listed on the Oslo Stock Exchange (Axess). The company is developing
therapeutic products based on its proprietary photochemical internalization
(PCI) technology. Originating from world leading research at the Norwegian
Radium Hospital, the PCI technology works by inducing triggered endosomal
release and may be used to unlock the true therapeutic potential of a wide array
of modalities, such as small molecules, ADCs and siRNA. Two programs are
currently in clinical development in patient populations with a high unmet
medical need; recurrent head and neck cancer (phase II) and bile duct cancer
(phase I/II).

The company is also developing PCI as a CTL induction technology for therapeutic
and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo
that PCI significantly increases the number of activated antigen-specific CTLs
(Cytotoxic T Lymphocytes) by enhancing the MHC I antigen presentation of antigen
presenting cells. When applied more specifically to the emerging field of cancer
immunotherapy, PCI can be used to enhance the important cytotoxic effect of
therapeutic cancer vaccines. PCI Biotech follows a strategy to create value by
improving the effect both of existing cancer drugs and by realizing the large
potential in new therapeutics, including therapeutic vaccines.

For more information visit: www.pcibiotech.com

Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 940 05 757
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.


[HUG#1905625]